# Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome

> **NCT01348087** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 148 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** AFQ056

## Key facts

- **NCT ID:** NCT01348087
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 148 (ACTUAL)
- **Why stopped:** Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212)
- **Last updated:** 2016-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01348087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01348087, "Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01348087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*